Clinical Trial Search Results for "LAPLACE-TIMI 57"

Desai, Nihar R., Kohli, Payal, Giugliano, Robert P., Kim, Jae B., Mohanavelu, Satishkumar, Hoffman, Elaine, Liu, Thomas, Scott, Robert, Wasserman, Scott, Sabatine, Marc S. AMG 145, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients Circulation. 2012;126(23):2791-2791.

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017. Abstract

Giugliano, Robert P., Desai, Nihar R., Kohli, Payal, Somaratne, Ransi, Huang, Fannie, Mohanavelu, Satishkumar, McDonald, Shannon T., Abrahamsen, Timothy E., Wasserman, Scott M., Scott, Robert, Sabatine, Marc S. LAPLACE-TIMI 57 Primary Results Circulation. 2012;126(23):2790-2791.

Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R., Huang, F., Knusel, B., McDonald, S., Abrahamsen, T., Wasserman, S. M., Scott, R., Sabatine, M. S. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy Clin Cardiol. 2012;35(7):385-91. Abstract

Desai, N. R., Giugliano, R. P., Zhou, J., Kohli, P., Somaratne, R., Hoffman, E., Liu, T., Scott, R., Wasserman, S. M., Sabatine, M. S. AMG 145, A Monoclonal Antibody Against PCSK9, Facilitates Achievement of NCEP-ATP III LDL-C Goals Among High Risk Patients: An Analysis From the LAPLACE-TIMI 57 Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Desai, N. R., Kohli, P., Giugliano, R. P., O'Donoghue, M. L., Somaratne, R., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., Scott, R., Sabatine, M. S. AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation. 2013;128(9):962-9. Abstract

Kohli, Payal, Giugliano, Robert P. Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents: The Discovery and Development of Promising Novel Targeted Therapies Journal of Cardiovascular Pharmacology and Therapeutics. 2013;18(3):199-210.